HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cammà, C. Articles by Cottone, M. Search for Related Content PubMed PubMed Citation Articles by Cammà, C. Articles by Cottone, M.

Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Meta-Analysis of Randomized Controlled Trials¹

¹ From the National Council of Research, Istituto Metodologie Diagnostiche Avanzate, Palermo, Italy (C.C); Department of Gastroenterology, Section of Clinical Medicine (C.C., A.C.) and Department of General Medicine and Pneumology (A.O., M.A., M.C.), University of Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy; Department of Experimental Medicine, Clinica G. Salvatore, University of Catanzaro, Italy (F.S.); Department of Internal Medicine, Cardiology, and Hepatology, University of Bologna, Italy (F.T., P.A.); and Fox Chase Cancer Center, Philadelphia, Pa (L.S.). Received July 23, 2001; revision requested September 28; revision received November 8; accepted January 8, 2002. Address correspondence to C.C. (e-mail: camma@ismeda.pa.cnr.it).

View larger version (29K): [in a new window]   Figure 1. Plot illustrates findings from meta-analysis of the overall 2-year mortality in five RCTs (seven comparisons) in which chemoembolization was performed for unresectable HCC. The bold vertical line represents the equivalence line (odds ratio of 1) between chemoembolization and nonactive treatment. Odds ratios of less than 1 (to the left of the equivalence line) favor chemoembolization, and odds ratios of greater than 1 (to the right of the equivalence line) favor nonactive treatment. When the error bar does not cross the equivalence line, a significant difference exists between treatment and control groups. Data are shown on a logarithmic scale. = the odds ratio for each trial and the overall estimate. The error bars represent the 95% CIs of each estimate. Lin refers to Lin et al (7), Group TCH refers to Groupe d’Étude et de Traitment du Carcinome Hépatocellulaire (12), Pellettier refers to Pellettier et al (13), Bruix refers to Bruix et al (14), and Llovet TACE and Llovet TAE refer to Llovet et al (43). #Pts = number of patients.

View larger version (17K): [in a new window]   Figure 2. Plot illustrates findings from the meta-regression analysis of an overall 2-year mortality odds ratio and 95% CIs according to different chemoembolization procedures. The bold solid vertical line represents the equivalence line (odds ratio of 1) between treatment and control (C) groups. Odds ratios of less than 1 (to the left of the equivalence line) favor treatment, and odds ratios of greater than 1 (to the right of the equivalence line) favor control group. When the error bar does not cross the equivalence line, a significant difference exists between treatment and control groups. Data are shown on a logarithmic scale. = the odds ratio for each comparison. The error bars represent the 95% CIs of each estimate. TAC = transarterial chemotherapy, #Pts = number of patients.